经导管主动脉瓣置换术后上消化道出血的发生率、预测因素及临床影响
该前瞻性TAVR注册研究纳入3144例患者,发现出院后1年内上消化道出血发生率为1.7%,其中40例为大出血或危及生命的出血;房颤/房扑和既往上消化道出血为独立预测因素,出院时使用质子泵抑制剂和高血红蛋白水平为保护因素;发生大出血或危及生命出血的患者全因死亡率和心血管死亡率显著升高。
要点
- TAVR术后1年内上消化道出血发生率为1.7%,其中多数为大出血或危及生命出血。
- 房颤/房扑和既往上消化道出血是独立预测因素,出院时PPI使用和高血红蛋白为保护因素。
- 大出血或危及生命出血与全因死亡和心血管死亡风险显著增加相关。
核心结论
- TAVR术后1年内1.7%患者发生上消化道出血,大出血或危及生命出血与全因和心血管死亡风险增加相关。
研究设计与样本
- 前瞻性TAVR注册研究,纳入3144例符合条件患者,按出院后1年内是否发生上消化道出血进行分层。
主要发现
- 3144例中54例(1.7%)出院后发生上消化道出血,其中40例为大出血或危及生命出血,14例为轻微出血。
- 房颤或房扑(HRadjusted 2.98;95% CI 1.65至5.38)和既往上消化道出血(HRadjusted 3.51;95% CI 1.51至8.19)为独立预测因素。
- 出院时使用质子泵抑制剂(HRadjusted 0.49;95% CI 0.27至0.89)和较高血红蛋白水平(每增加1 g/dL,HRadjusted 0.73;95% CI 0.62至0.87)为保护因素。
- 发生大出血或危及生命上消化道出血的患者较无上消化道出血者全因死亡率更高(73.7% vs 11.4%,HR 5.84;95% CI 3.41至10.02)。
- 发生大出血或危及生命上消化道出血的患者心血管死亡率更高(31.6% vs 7.3%,HR 3.87;95% CI 1.72至8.70)。
临床怎么用
- 对TAVR术后患者应评估上消化道出血风险,尤其关注房颤/房扑和既往上消化道出血病史。
- 出院时使用质子泵抑制剂可能与较低的上消化道出血风险相关,高血红蛋白水平亦为保护因素。
- 发生大出血或危及生命上消化道出血的TAVR术后患者死亡风险显著增高,需加强监测和管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Upper gastrointestinal (GI) bleeding following transcatheter aortic valve replacement (TAVR) is common in patients with aortic stenosis due to the combination of acquired type 2A von Willebrand disease and aspirin-based antiplatelet therapy. We aimed to investigate the incidence, predictors and clinical outcomes of late upper GI bleeding in patients undergoing TAVR. METHODS: In a prospective TAVR registry, patients were stratified according to upper GI bleeding within 1 year of discharge. RESULTS: Among the 3144 eligible patients, 54 (1.7%) experienced upper GI bleeding after discharge. Of these, 40 patients had major or life-threatening bleeding, while 14 had minor bleeding events. The presence of atrial fibrillation or atrial flutter (HRadjusted 2.98; 95% CI 1.65 to 5.38) and previous upper GI bleeding (HRadjusted 3.51; 95% CI 1.51 to 8.19) were independent predictors of upper GI bleeding, while the use of proton pump inhibitors at discharge (HRadjusted 0.49; 95% CI 0.27 to 0.89) and higher haemoglobin levels (1 g/dL increase) (HRadjusted 0.73; 95% CI 0.62 to 0.87) were protective. Patients who experienced major or life-threatening upper GI bleeding had a higher all-cause (73.7% vs 11.4%, HR 5.84; 95% CI 3.41 to 10.02) and cardiovascular mortality (31.6% vs 7.3%, HR 3.87; 95% CI 1.72 to 8.70) compared with those without upper GI bleeding. CONCLUSIONS: Among patients who underwent TAVR, 1.7% of patients experienced upper GI bleeding within 1 year of discharge. Major or life-threatening upper GI bleeding was associated with an increased risk of all-cause and cardiovascular mortality. TRIAL REGISTRATION NUMBER: NCT01368250.
引用
- Nakase M, Draxler DF, Tomii D, et al. Incidence, predictors and clinical impact of upper gastrointestinal bleeding after transcatheter aortic valve replacement. Heart. 2025. PMID: 40348411. doi:10.1136/heartjnl-2024-325359
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。